Exploring the efficacy of our newly patented catalytic compounds designed specifically to increase yield in complex active pharmaceutical ingredient (API) synthesis.
Recent trials indicate that the proprietary catalyst, codenamed X-72, increases overall synthesis yield by up to 18% while simultaneously reducing toxic byproducts. This represents a massive cost and safety optimization for our pharmaceutical manufacturing partners.
We are currently entering Phase 3 scale-up testing, with commercial availability slated for early next year.